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Background
Prescription of drugs must follow established guidelines,
especially concerning maximum daily dose. Nevertheless
some clinicians and researchers often try high doses for
optimizing results. Patients also tend to raise the doses
especially of anxiolytics and analgetics
Materials and methods
We present a case report of a dysthymic patient who, by
his own decision and against the doctor's recommenda-
tions, continuously receives venlafaxine at a dose almost
double than the officially maximum recommended
Results
A 38 year old man who suffered of dysthymia following a
head injury after a car crash, presented for treatment. He
had no permanent neurological and cognitive conse-
quences except from dizziness. Treatment started with
venlafaxine, as another agent tried before proved ineffi-
cient. Following titration the psychiatrist recommended
the dose of 300mgs per day by means of XR capsules. The
recommended maximum daily dose of the certain drug is
325mgs. At the following visits his condition had
improved but with no complete remission. During the
regular once-per-month follow-up the patient announced
that he had by his own decision increased the dose to
600mg daily, and he felt much better. Despite the contin-
uous precautions given by the doctor about the maximum
dose and the possible harm he insisted to his initial deci-
sion managing to obtain the extra amount by means of
private purchasing. The tests he underwent for liver and
renal function were normal, and the ECG showed moder-
ate elevation of heart rate. He suffers minor side-effects
like constipation and dry mouth. He continues to do so
for 2 years now.
Conclusions
The above case report is presented for discussion in two
topics. A. the limits of dose-related response of venlafax-
ine, and B. the possible altered pharmacokinetics of ven-
lafaxine in certain patients.
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